NCT01911377View on ClinicalTrials.gov

Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS

PHASE2TerminatedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

August 31, 2015

Conditions

Neuropathic PainAllodynia

Interventions

DRUG

Botulinum Toxin Type A

DRUG

Normal Saline for Injection

Trial Locations (1)

R3A IM4

WRHA Health Sciences Centre Rehabilitation Hospital, Winnipeg

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Allergan

INDUSTRY

lead

University of Manitoba

OTHER